 CHICAGO--BUSINESS WIRE--Xeris Pharmaceuticals, Inc. Xeris, a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc Nasdaq: SBBP Strongbridge. Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin 